PMID: 9435871Jan 22, 1998Paper

Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins

Cancer Immunology, Immunotherapy : CII
L M WeinerM von Mehren

Abstract

Commencing with the discovery and characterization of bispecific antibodies, numerous investigations have shown that such antibodies are capable of redirecting cellular cytotoxicity. Clinical trials testing diverse strategies, including those targeting CD16-expressing effector cells, have been conducted or are in progress. This manuscript reviews our clinical trials efforts with bispecific antibodies and describes our experience employing multi-functional binding proteins containing tumor-targeting antibody Fab fragments linked to bacterial superantigens, such as staphylococcal enterotoxin A.

Citations

Mar 17, 2001·International Journal of Cancer. Journal International Du Cancer·O ManzkeH Bohlen
Nov 5, 2002·Clinical Biochemistry·Hassan M E Azzazy, W Edward Highsmith
Aug 8, 2002·Journal of Immunological Methods·Dan LuZhenping Zhu
Sep 13, 2003·Journal of Immunological Methods·Dan LuZhenping Zhu
Dec 21, 2014·International Immunopharmacology·Liming XuDeshan Li
Dec 22, 1999·The Tohoku Journal of Experimental Medicine·T KudoS Matsuno

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.